西妥昔单抗:表皮生长因子受体的单克隆抗体治疗结直肠癌。

文章的细节

引用
复制到剪贴板

黄科幻

西妥昔单抗:表皮生长因子受体的单克隆抗体治疗结直肠癌。

其他。2005年6月,27 (6):684 - 94。doi: 10.1016 / j.clinthera.2005.06.003。

PubMed ID
16117976 (在PubMed
]
文摘

背景:西妥昔单抗是一种重组体人/鼠嵌合表皮生长因子受体(EGFR)单克隆抗体。这是美国食品和药物管理局批准的2004年2月使用结合EGFR-expressing伊立替康治疗,转移性结直肠癌患者中未能改善irinotecan-based化疗。西妥昔单抗也批准了政府作为单药治疗的患者EGFR-expressing,转移性结直肠癌那些不能容忍irinotecan-based化疗。目的:本文综述西妥昔单抗的作用,一个EGFR单克隆抗体,在结直肠癌的治疗。方法:医学研究发表的文章进行了从1976年到现在使用西妥昔单抗,C225, IMC-C225,结肠癌,直肠癌,单克隆疗法,和目标疗法。摘要发表在美国临床肿瘤学会年会从2000年到2004年和2004年的胃肠道癌症研讨会综述,包括适用。结果:在第三期临床试验,西妥昔单抗为329名患者结直肠癌伊立替康耐火材料和/或未能应对铂治疗。局部反应是在10.8%的患者接受了西妥昔单抗单药治疗,22.9%的患者接受了西妥昔单抗+伊立替康治疗(P = 0.007)。2二期试验使用的总体响应率传统的给药方案是西妥昔单抗治疗EGFR-expressing,转移性结直肠癌,耐火伊立替康治疗范围从9%到12%。该疫苗的人体耐受性很好通过适当的管理措施。 The most common adverse events reported included acnelike rash and hypersensitivity reaction. The positive correlation of the incidence of skin reactions to response rates and median survival is one aspect that warrants further investigation in terms of its use as a response predictor. Unfortunately, the role of immunohistochemistry for EGFR expression continues to be a poor predictor of patients who may benefit from cetuximab. Clinical studies are ongoing of cetuximab in combination with radiation therapy and/or platinum in patients with squamous cell head and neck cancer, as well as cetuximab in combination with various antineoplastic agents in the treatment of non-small cell lung cancer and pancreatic cancer. CONCLUSIONS: Cetuximab has shown considerable activity-both as monotherapy and in combination with chemotherapy-in the treatment of metastatic colorectal cancer that is resistant to chemotherapy. The future of cetuximab lies in its use in combination with antineoplastic agents and/or radiation therapy in the treatment of colorectal cancer, head and neck cancer, non-small cell lung cancer, and pancreatic cancer. The lack of a predictive marker that would allow clinicians to select patients who are most likely to benefit from cetuximab therapy, especially taking into consideration the high costs of this medication, remains a challenge.

beplay体育安全吗DrugBank数据引用了这篇文章

药物